Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093508 | 0.88 | MAPT (0.58) | KMT2AMEN1HDAC2HDAC3HDAC1 | |
| SCHEMBL5090088 | 0.87 | RAB9A (0.62) | KMT2AMEN1HDAC2HDAC3HDAC1 | |
| SCHEMBL5101866 | 0.87 | HDAC3 (0.64) | KMT2AMEN1HDAC2HDAC3HDAC1 | |
| SCHEMBL5214482 | 0.78 | SMN1; SMN2 (0.50) | KMT2AMEN1HDAC2ALDH1A1NPC1 | |
| SCHEMBL15747587 | 0.76 | ALDH1A1 (0.71) | KMT2AMEN1HDAC2HDAC3HDAC1 | |
| SCHEMBL5101919 | 0.76 | HDAC3 (0.65) | HDAC2HDAC3HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5096066 | 0.76 | HDAC3 (0.53) | KMT2AMEN1HDAC2HDAC3HDAC1 | |
| SCHEMBL4729283 | 0.75 | ALDH1A1 (0.63) | HDAC2HDAC3HDAC1ALDH1A1NPC1 | |
| SCHEMBL5101918 | 0.74 | CYP1A2 (0.64) | KMT2AMEN1HDAC2HDAC3HDAC1 | |
| SCHEMBL5093565 | 0.74 | HDAC3 (0.64) | HDAC2HDAC3HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | GPC BIOTECH AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1833832-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC Biotech AG (DE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007060028-A1 | NAPTHYRIDINE COMPOUNDS AS ROCK INHIBITORS | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207677-A1 | Napthyridine Compounds As Rock Inhibitors | ROCK2, ROCK1, RHOT2 | KMT2A 3311/4885MEN1 1318/4885HDAC2 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.